Skip to main
ENGN

ENGN Stock Forecast & Price Target

ENGN Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 25%
Buy 38%
Hold 38%
Sell 0%
Strong Sell 0%

Bulls say

enGene Therapeutics is a clinical-stage biotechnology company with a positive outlook due to its pioneering program, detalimogene, for patients with Non-Muscle Invasive Bladder Cancer. The company's proprietary Dually Derivatized Oligochitosan platform and promising results from its ongoing multi-cohort LEGEND Phase 2 trial demonstrate potential for future success in addressing high clinical needs. However, the recent lower market share assumptions and lower probability of success for detalimogene in NMIBC raise concerns and may impact the company's valuation. The upcoming AUA plenary presentation and data on the polidocanol bladder rinse cohort will be critical in determining the potential for failure patterns, durability, and progression.

Bears say

enGene Therapeutics is facing a challenging road ahead as the efficacy of its lead drug, detalimogene, has declined significantly in its interim analysis. This decline is particularly driven by recently enrolled patients, indicating a potential lack of consistency in the drug's mechanism of action. Additionally, the company's CMO may be departing, creating further uncertainty for the company's future. As a result, the financial analyst has downgraded enGene Therapeutics to Neutral and has lowered their price target to $6. Further risks to achieving this price target include clinical, regulatory, and competitive factors.

ENGN has been analyzed by 8 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 38% recommend Buy, 38% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Engene Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Engene Holdings Inc (ENGN) Forecast

Analysts have given ENGN a Buy based on their latest research and market trends.

According to 8 analysts, ENGN has a Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.19, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.19, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Engene Holdings Inc (ENGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.